Suchergebnisse - "Subbiah, Vivek"

PubPharm (42)

1

RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers : the RE-RAFFLE study

enthalten in: Molecular cancer | 2024

von Nelson, B. | Roszik, J. | Ahmed, J. | +11

2

Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma : A Case Series

enthalten in: Clinical lung cancer | 2023

von Fricke, J. | Wang, J. | Gallego, N. | +7

3

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations

enthalten in: Cancer discovery | 2023

von Subbiah, V. | Sahai, V. | Maglic, D. | +28

CommentIn: Cancer Discov. 2023 Sep 6;13(9):1964-1965. - PMID 37671472

4

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

enthalten in: Cancer chemotherapy and pharmacology | 2023

von Piha-Paul, S. | Tseng, C. | Tran, H. | +13

5

RET aberrant cancers and RET inhibitor therapies : Current state-of-the-art and future perspectives

enthalten in: Pharmacology & therapeutics | 2023

von Addeo, A. | Miranda-Morales, E. | den Hollander, P. | +5

6

Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer : Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Drilon, A. | Subbiah, V. | Gautschi, O. | +15

CommentIn: J Clin Oncol. 2023 Jan 10;41(2):410-412. - PMID 36122320

7

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001) : a phase 1/2, open-label, basket trial

enthalten in: The Lancet. Oncology | 2022

von Subbiah, V. | Wolf, J. | Konda, B. | +12

CommentIn: Lancet Oncol. 2022 Oct;23(10):1235-1237. - PMID 36108663

8

Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations : case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response

enthalten in: Journal of hematology & oncology | 2022

von Persha, H. | Kato, S. | De, P. | +4

9

Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors

enthalten in: JCO precision oncology | 2022

von Dankner, M. | Wang, Y. | Fazelzad, R. | +26

10

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors

enthalten in: Molecular cancer therapeutics | 2022

von Adashek, J. | Menta, A. | Reddy, N. | +3

1
2
3
4
5
Nächster »
[5]